More time for women with recurrent ovarian cancer, regardless of BRCA mutation status

More Time for Women Regardless of BRCA Mutation Status

ZEJULA is the first and only once-daily PARP inhibitor for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.1-3

See the NOVA Trial Data

The primary end point of the pivotal trial was PFS from time of randomization to time of disease progression or death. At the time of the PFS analysis, limited overall survival data were available, with 17% of planned survival events occurring in the study (HR=0.73; 95% CI, 0.48-1.13), P=0.15.1,4,5

Median PFS in the pivotal trial:

Median progression-free survival was 21 months in gBRCAmut cohort of patients on ZEJULA vs. 5.5 months in patients on placebo
Median progression-free survival was 9.3 months in non-gBRCAmut cohort of patients on ZEJULA vs. 3.9 months in patients on placebo

BRCA, breast cancer susceptibility gene; CI, confidence interval; gBRCAmut, germline BRCA mutated; HR, hazard ratio; non-gBRCAmut, not germline BRCA mutated; PARP, poly(ADP-ribose) polymerase; PFS, progression-free survival.

Sign-up for more information


Sign up for updates or request a rep

Efficacy data


View PFS by cohort, including non-gBRCAmut

View Efficacy
Safety data


Learn about the safety and tolerability of ZEJULA

See Safety
Back to Top